Daktari Biotechnology Ltd, a company specializing in medicines and vaccines, is one of the Micro, Small, and Medium Enterprises (MSMEs) located at the Diaspora University Town (DUT). Dr. Wilson Endege and other scientists founded the company. Diaspora Kenyans and Kenyans have launched the Founder Angel Investment initiative, aiming to raise Ksh 1.5 billion through 60,000 investments of Ksh 25,000 ($200). The investment period ends on June 30, 2025, or once 60,000 investments have been made.
An angel investor is an individual who invests capital in a business for equity ownership, primarily in the form of share capital. The primary goals of investment are to support the production of products and services that sustain humanity and the environment, while generating a return on investment. Reports indicate that there are approximately 400,000 angel investors in the U.S., who invest around $30 billion each year.
Grace Njuguna of Anaheim, CA, is the first founder angel investor and, as such, the initiator of the Diaspora Kenyans founder angel investor system.
Dr. Nelly Kangethe (RN) of Baltimore, MD, USA, is the first Diaspora nurse to join the scientists. Dr. Endege has called for Diaspora nurses whose careers involve administering medicines to join Daktari Biotechnology as founder angel investors. She has answered the call.
Charles Muriu of London, UK, has started the European Diaspora Kenyans founder angel investor list.
Diaspora Kenyans' founder angel capital will play a significant role in Kenya's GDP growth, from the current $110 billion (Ksh 14 trillion) to surpass the $200 billion (Ksh 20 trillion) mark by 2030. Thereafter, the angel investors will pass the baton to the next generation of angel investors to achieve the Kenya GDP growth of $2 trillion by 2075.
Dr. Endege has a plan, which will commence on July 1, 2025, and conclude on December 31, 2030. The plan will progressively grow to reach over 100 million units of tablets and liquid products of medicines and vaccines, produced at the plant.
The plan aims to create over 1,000 jobs and is projected to generate a yearly revenue of Ksh 20 billion by 2030, as the Kenyan GDP is expected to grow by more than Ksh 6 trillion. The Ksh 25,000 founder angel investment is planned to yield a Ksh 10,000 dividend from the Ksh 20 billion revenue.
Prof. Dr. David Ogoli has finished the design of the medicine and vaccine plant. Once the founder angel investors invest the planned capital, the plant construction will progress. Within two years, the plant is expected to be completed, and production of medicines and vaccines is anticipated to commence.
The pharmacy arm of the company will begin operations as construction starts at Diaspora University Town. The pharmacy will serve the workers, who are expected to grow to 15,000 by 2030. Additionally, the town is expected to have 25,000 residents, 5,000 students, and 1 million visitors a year by 2030.
The company will open approximately eight pharmacies at DUT to provide medicine and vaccines. By 2030, the company's goal is to have opened 100 pharmacies and have a market share of at least 10% in the Kenyan medication and vaccine market, both in production and dispensing medications.
